Business Context and Reporting Period
This Form 6-K filing covers the month of May 2014 for Prana Biotechnology Limited (ASX:PBT), a foreign private issuer headquartered in Parkville, Victoria, Australia. The filing serves as an Initial Director's Interest Notice submitted to the Australian Securities Exchange (ASX) and furnished to the SEC pursuant to Rule 12g3-2(b).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director interests and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed in this filing is the appointment of Professor Ira Shoulson as a director on May 13, 2014. The filing details his relevant interests in the company's securities and contracts at the time of appointment.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly adheres to the requirements of ASX Listing Rule 3.19A.1 and Section 205G of the Corporations Act regarding director disclosures.
Important Facts for Investors
- Director Appointment: Professor Ira Shoulson was appointed as a director on May 13, 2014.
- Securities Holdings: Professor Shoulson holds Nil registered securities of the company (Part 1).
- Unregistered Interests: Professor Shoulson has Nil relevant interests in securities of which he is not the registered holder (Part 2).
- Contractual Interests: Professor Shoulson has Nil interests in contracts with the company (Part 3).
- Company Identity: The registrant is Prana Biotechnology Limited (ABN: 37 080 699 065), not Altery Therapeutics Ltd as indicated in the request metadata.